Abstract
BackgroundVenous thromboembolic co-morbidities can have a significant impact on treatment response, treatment options, quality of life, and ultimately, survival from cancer. The extent of venous thromboembolic co-morbidity among older renal cell cancer patients is poorly described in the literature. It is important to understand the scope of venous thromboembolic events, before and after diagnosis, in order to offer renal cell cancer patients optimal care and improved quality of life.MethodsThe main goal of this study was to estimate and describe the incidence of venous thromboembolic events before and after renal cell cancer diagnosis. SEER-Medicare linked data (1991–2003) was utilized for this retrospective cohort analysis (n = 11,950) of older renal cell cancer patients (≥ 65 years). Incidence rates and proportions in addition to multivariable Cox proportional hazard and logistic regression models were utilized to describe the incidence and relative risk of venous thromboembolic events.ResultsWe observed that in the 12 months after diagnosis, 8.3% of renal cell cancer patients experienced a deep venous thrombosis, 2.4% experienced a pulmonary embolism, and 3.9% experienced other thromboembolic events. Nearly 70% of venous thromboembolic events occurred in the first 90 days after renal cell cancer diagnosis. Renal cell cancer patients were 2–4 times more likely to have a venous thromboembolic event in the 12 months after cancer diagnosis than non-cancer patients followed during the same time frame. Recent history of a venous event substantially increased the risk of that same event in the 12 months after diagnosis (HR = 5.2-18.8).ConclusionVenous thromboembolic events are common and serious co-morbidities that should be closely monitored in older renal cell cancer patients, particularly during the first 3 months following diagnosis and among those with a recent history of a venous thromboembolic event.
Highlights
Venous thromboembolic co-morbidities can have a significant impact on treatment response, treatment options, quality of life, and survival from cancer
Of all Venous thromboembolic event (VTE) that occurred after diagnosis, deep vein thrombosis (DVT) occurred at the highest rate (108/ 1,000 person-years)
Our results suggest that VTE history is the most important factor to consider in evaluating risk of future VTE in renal cell cancer (RCC) patients
Summary
Venous thromboembolic co-morbidities can have a significant impact on treatment response, treatment options, quality of life, and survival from cancer. It is important to understand the scope of venous thromboembolic events, before and after diagnosis, in order to offer renal cell cancer patients optimal care and improved quality of life. A small body of evidence is developing for brain, breast, lung, ovarian, and pancreatic cancers, suggesting that the incidence of VTEs varies substantially by cancer subtype [2,5,6,7,8,9,10,11,12,13,14] Estimates for these cancers range from as low as 0.4% up to 26.0%, depending on the cancer type, study population, and the length of follow-up [13]. It is important to understand the scope of VTEs, before and after diagnosis, in order to offer RCC patients optimal care and improved quality of life
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
